Samlyn Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Samlyn Capital’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-953,711	Closed	-$14.2M	–	153
2019 Q2	$14.2M	Buy	953,711 +582,871	+157%	+$10.5M	0.3%	80
2019 Q1	$9.2M	Sell	370,840 -634,397	-63%	-$15.9M	0.22%	83
2018 Q4	$18.1M	Buy	+1,005,237	New	+$20.5M	0.43%	67
2018 Q2	–	Sell	-308,119	Closed	-$16.3M	–	169
2018 Q1	$16.3M	Sell	308,119 -376,417	-55%	-$22M	0.36%	81
2017 Q4	$46.5M	Buy	684,536 +162,191	+31%	+$11.3M	1.07%	39
2017 Q3	$43M	Sell	522,345 -45,355	-8%	-$3.6M	1.09%	32
2017 Q2	$53.2M	Buy	567,700 +322,800	+132%	+$19.8M	1.3%	30
2017 Q1	$15.6M	Sell	244,900 -658,900	-73%	-$40.1M	0.36%	77
2016 Q4	$40.1M	Buy	903,800 +373,889	+71%	+$13.2M	0.91%	47
2016 Q3	$19.1M	Sell	529,911 -148,499	-22%	-$3.19M	0.45%	78
2016 Q2	$9.31M	Buy	+678,410	New	+$9.92M	0.22%	83

Other funds holding CLVS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Samlyn Capital's CLVS Position: Q3 2019 in Review

Samlyn Capital sold out of Clovis Oncology, Inc. (CLVS) in Q3 2019, closing a stake of 953,711 shares — an estimated $14.2M sold.

Samlyn Capital first reported a position in CLVS in Q2 2016 and held it in 11 quarters. The position peaked at $53.2M in Q2 2017. 153 funds tracked by Wall St. Rank hold CLVS as of Q3 2019.

Samlyn Capital reported no remaining Clovis Oncology, Inc. position as of Q3 2019 after selling out during the quarter.
Samlyn Capital sold 953,711 Clovis Oncology, Inc. shares in Q3 2019, an estimated $14.2M.
Samlyn Capital first reported a position in Clovis Oncology, Inc. in Q2 2016 and held it in 11 quarters.
Samlyn Capital's Clovis Oncology, Inc. position peaked at $53.2M in Q2 2017.
153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2019.

Based on Samlyn Capital's 13F filing for Q3 2019, filed 14 Nov 2019.